Literature DB >> 16546581

Psoriasis is associated with lipid abnormalities at the onset of skin disease.

Lotus Mallbris1, Fredrik Granath, Anders Hamsten, Mona Ståhle.   

Abstract

BACKGROUND: Psoriasis appears to have increased cardiovascular morbidity. The underlying pathogenetic mechanisms remain unclear. Multiple factors, including systemic inflammation, oxidative stress, aberrant lipid profile, and concomitant established risk factors, have been discussed. However, previous studies consist of heterogeneous patient materials, including persons with highly varying disease duration and treatment.
METHODS: Two-hundred patients were investigated at the onset of psoriasis, comparing plasma concentrations of lipids, lipoproteins, and apolipoproteins with those of matched controls (N = 285).
RESULTS: Psoriasis patients manifest significant lipid abnormalities. Specifically, patients had significantly higher cholesterol concentrations in the very-low-density lipoprotein and high-density-lipoprotein fractions. Adjustment for established environmental risk factors did not affect the results. LIMITATION: The response rate among control subjects was low. However, an additional analysis of a random subset of nonresponders demonstrated no substantial differences in the main results.
CONCLUSION: The study supports the notion that lipid abnormalities in psoriasis may be genetically determined rather than acquired.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16546581     DOI: 10.1016/j.jaad.2005.11.1079

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  66 in total

Review 1.  Metabolic disorders in patients with psoriasis and psoriatic arthritis.

Authors:  Lotus Mallbris; Christopher T Ritchlin; Mona Ståhle
Journal:  Curr Rheumatol Rep       Date:  2006-10       Impact factor: 4.592

2.  Lipid profile and metabolic syndrome status in patients with oral lichen planus, oral lichenoid reaction and healthy individuals attending a dental college in northern India - a descriptive study.

Authors:  Bhuvana Krishnamoorthy; Suma Gn; Mamatha N S; Sowbhagya M B; Komali Garlapati
Journal:  J Clin Diagn Res       Date:  2014-11-20

3.  Association between osteoporosis and psoriasis: results from the Longitudinal Health Insurance Database in Taiwan.

Authors:  J J Keller; J-H Kang; H-C Lin
Journal:  Osteoporos Int       Date:  2012-10-07       Impact factor: 4.507

4.  Association between rs662 (A > G) and rs854560 (A > T) polymorphisms in PON1 gene and the susceptibility for psoriasis in mestizo population of Western Mexico.

Authors:  A A Hernández-Collazo; Oscar Pérez-Méndez; Victoria López-Olmos; V Delgado-Rizo; J F Muñoz-Valle; Erika Martínez-López; D G Villanueva-Quintero; Carolina Domínguez-Díaz; Mary Fafutis-Morris; Anabell Alvarado-Navarro
Journal:  Mol Biol Rep       Date:  2020-12-07       Impact factor: 2.316

Review 5.  Lipid disturbances in psoriasis: an update.

Authors:  Aldona Pietrzak; Anna Michalak-Stoma; Grazyna Chodorowska; Jacek C Szepietowski
Journal:  Mediators Inflamm       Date:  2010-07-20       Impact factor: 4.711

Review 6.  Ustekinumab: a new option in psoriasis therapy.

Authors:  Anna L Chien; James T Elder; Charles N Ellis
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

Review 7.  Psoriasis and metabolic disease: epidemiology and pathophysiology.

Authors:  Rahat S Azfar; Joel M Gelfand
Journal:  Curr Opin Rheumatol       Date:  2008-07       Impact factor: 5.006

8.  Factors associated with the length of remission of psoriasis vulgaris.

Authors:  Susana Coimbra; Hugo Oliveira; Américo Figueiredo; Petronila Rocha-Pereira; Alice Santos-Silva
Journal:  Clin Drug Investig       Date:  2013-11       Impact factor: 2.859

9.  Keratinocyte but not endothelial cell-specific overexpression of Tie2 leads to the development of psoriasis.

Authors:  Julie A Wolfram; Doina Diaconu; Denise A Hatala; Jessica Rastegar; Dorothy A Knutsen; Abigail Lowther; David Askew; Anita C Gilliam; Thomas S McCormick; Nicole L Ward
Journal:  Am J Pathol       Date:  2009-04       Impact factor: 4.307

10.  [Comorbidities in psoriatic arthritis].

Authors:  W-H Boehncke; S Boehncke
Journal:  Z Rheumatol       Date:  2013-10       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.